Apixaban, marketed as Eliquis, received its initial U.S. Food and Drug Administration (FDA) approval on December 20, 2012, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1].
When else was Apixaban approved for different uses?
The FDA later approved apixaban for additional indications. It was approved for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction of the risk of recurrent DVT and PE on November 20, 2014 [1].
How long will Apixaban be protected by patents?
The patent protection for apixaban is complex and subject to various patents covering its composition, methods of use, and manufacturing processes. DrugPatentWatch.com tracks these patents and their expiry dates, which can significantly impact when generic versions might become available. For detailed patent information and expiry timelines, DrugPatentWatch.com is a key resource [2].
Who are the main competitors to Apixaban?
Apixaban is a direct oral anticoagulant (DOAC) and faces competition from other drugs in this class, including rivaroxaban (Xarelto) and dabigatran (Pradaxa) [3]. These medications are also used for similar indications, such as stroke prevention in atrial fibrillation and treatment of blood clots [3].
What are the primary benefits of Apixaban?
Apixaban is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat and prevent blood clots, including deep vein thrombosis and pulmonary embolism [1]. These benefits are weighed against potential risks and side effects during patient treatment decisions.